Johnson & Johnson (JNJ)vsNeuropace Inc (NPCE)
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
NPCE
Neuropace Inc
$12.93
-0.69%
HEALTHCARE · Cap: $443.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 92743% more annual revenue ($99.33B vs $106.99M). JNJ leads profitability with a 16.2% profit margin vs -17.9%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
NPCE
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Margin of Safety
-18.0%
Fair Value
$12.34
Current Price
$12.93
$0.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
17.1% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 36.9x book value
ROE of -160.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : NPCE
The strongest argument for NPCE centers on Revenue Growth. Revenue growth of 17.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : NPCE
The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NPCE is a growth play — different risk/reward profiles.
NPCE carries more volatility with a beta of 1.87 — expect wider price swings.
NPCE is growing revenue faster at 17.1% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 27/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Neuropace Inc
HEALTHCARE · MEDICAL DEVICES · USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?